New hope for cervical cancer: 1,300 patients to test drug combinations
Disease control
Not yet recruiting
This study will follow 1,300 people with cervical cancer that has spread or come back. Participants will take one or two drugs called camrelizumab and famitinib, alone or with other treatments. The goal is to see how safe and effective these options are in real-world use.
Sponsor: Qi Zhou • Aim: Disease control
Last updated May 16, 2026 10:04 UTC